Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005970 · ClinicalTrials.gov registry record · Phase 3
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,436
- Enrollment target
NCT00005970: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00005970 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3,436 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005970, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,436 participants
- Enrollment target
Study Summary
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer.
Interventions
- DRUG Cyclophosphamide
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- DRUG Doxorubicin Hydrochloride
- DRUG Aromatase Inhibition Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,436 participants |
| Start Date | 2000-05-19 |
| Est. Completion | 2010-01-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005970
The ClinicalTrials.gov registry entry for NCT00005970 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,436 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00005970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005970 about?
NCT00005970 is a clinical study titled "Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer". This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread t...
What is the current status of trial NCT00005970?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,436 participants. The study started on 2000-05-19. Estimated completion is 2010-01-27.
What interventions are being tested in trial NCT00005970?
The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Doxorubicin Hydrochloride (DRUG), Aromatase Inhibition Therapy (DRUG).
Who is sponsoring clinical trial NCT00005970?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.